Conmed Corporation ( (CNMD) ) has released its Q1 earnings. Here is a breakdown of the information Conmed Corporation presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CONMED Corporation, a medical technology company specializing in surgical devices and equipment, has reported its financial results for the first quarter of 2025. The company operates in various medical specialties, including orthopedics and general surgery.
In the first quarter of 2025, CONMED Corporation achieved sales of $321.3 million, marking a 2.9% increase year-over-year. The company’s domestic revenue grew by 4.2%, while international revenue saw a 1.2% increase. Adjusted diluted net earnings per share rose to $0.95 from $0.79 in the previous year, despite a decrease in GAAP diluted net earnings per share from $0.63 to $0.19.
Key financial metrics highlight a strong performance in single-use products with a 4.4% increase in sales, while capital products experienced a decline. The company’s adjusted EBITDA rose to $61.3 million from $56.3 million in the previous year, indicating improved operational efficiency. CONMED’s gross profit margin also saw a slight increase to 55.3% from 55.1%.
Looking ahead, CONMED Corporation has adjusted its full-year revenue expectations to reflect a more favorable foreign currency environment, anticipating revenue between $1.350 billion and $1.378 billion. The company also expects adjusted diluted net earnings per share to range between $4.45 and $4.60, reflecting confidence in its growth strategies despite potential tariff impacts later in the year.